News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
Lipid-lowering agents for nephrotic syndrome.
|Title||Lipid-lowering agents for nephrotic syndrome.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L|
|Journal||The Cochrane database of systematic reviews|
|Date Published||2013 Dec 10|
Nephrotic syndrome is the collective name given to a group of symptoms that include proteinuria, lipiduria, hypoalbuminaemia, oedema, hypercholesterolaemia, elevated triglycerides, and hyperlipidaemia. Hyperlipidaemia is thought to aggravate glomerulosclerosis (hardening of blood vessels in the kidneys) and enhance progression of glomerular disease. Studies have established that reduction in total cholesterol and low density lipoprotein (LDL) cholesterol is associated with reduction in risk of cardiovascular diseases. In 2011, the European Society of Cardiology and European Atherosclerosis Society guidelines for the management of dyslipidaemia recommended use of statins as first-line agents in the management of nephrotic dyslipidaemia. However, the effectiveness and safety of statins for people with nephrotic syndrome remains uncertain. Furthermore, the efficacy of second-line lipid-lowering drugs, such as ezetimibe and nicotinic acid, has not been proven in patients with nephrotic syndrome who are unable to tolerate statin therapy.
|Alternate Journal||Cochrane Database Syst Rev|